Global Acyclovir Drug Market
Global Acyclovir Drug Market

Acyclovir Drug Comprehensive Study by Application (Hospital, Drug Store), Form (Oral, Topical, Injection), Distribution Channel (Hypermarkets/Supermarkets, Drugstores, Online Retails, Independent Retailers and Discounters) Players and Region - Global Market Outlook to 2024

Acyclovir Drug Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Sep 2019 Edition 213 Pages 210 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Acyclovir Drug Market Scope
Acyclovir is an antiviral drug. It helps to treat the herpes virus in the body. This is not cured of the roots but it helps to lessen the symptoms of the infection. It used in the treatment of herpes viruses such as genital herpes, cold sores, shingles, chickenpox, as well as varicella, and cytomegalovirus. As Herpes infection is contagious in nature, it infected by contact with other people. While pregnancy itís very important to treat herpes, in these cases acyclovir drug is the best option to deal with it.

The market study is being classified, by Application (Hospital and Drug Store) and major geographies with country level break-up.

The global Acyclovir Drug market is highly competitive and consists of some key players. In terms of market share, few of the key players presently dominate the global market. These market players are leveraging on strategic collaborative creativities to intensification their market share and escalation their profitability. Research Analyst at AMA predicts that Germany Players will contribute to the maximum growth of Global Acyclovir Drug market throughout the predicted period.

GSK (United Kingdom), Zydus Pharmaceuticals (United States), Mylan (United States), Bausch Health (Canada), Vectans Pharma (France), Fresenius Kabi (Germany), Aurobindo Pharma (India), Teva Pharmaceutical Industries (Israel), Heritage Pharmaceuticals (United States) and APOTEX (Canada) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Cadila Pharmaceuticals (India), Amneal Pharmaceuticals (United States), Taro Pharmaceutical (United States), Glenmark (India), G&W Laboratories (United States), Yiling Pharmaceutical Ltd. (China) and Alembic Pharmaceuticals (India).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Acyclovir Drug market by Type, Application and Region.

On the basis of geography, the market of Acyclovir Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Form, the sub-segment i.e. Oral will boost the Acyclovir Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hypermarkets/Supermarkets will boost the Acyclovir Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In Feb 2019, Sol-Gel Technologies Ltd. focused on developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company announced the approval from the United States Food and Drug Administration.
In Apr 2019, the Food and Drug Administration (FDA) approved a new drug application for Avaclyr. Acyclovir is the gold standard treatment in herpes virus infection, it provides therapy inform of the ophthalmic dosage form.

Market Trend
  • Technology Advancement in Manufacturing Processes

Market Drivers
  • Increasing Number of Drug Stores in Emerging Countries
  • Rising Number of Skin Infection Diseases Especially With Pregnant Women
  • Growing Demand for Topical Dermatological Drugs

Opportunities
  • Initiatives Government Initiatives to Help Skin Infection Patients

Restraints
  • Rapid Changes in Technology
  • Rising Cost of Raw Materials
  • Strict Government Regulations

Challenges
  • Increasing Side Effects Such As Nausea, Vomiting, Diarrhoea, General Ill Feeling, Headache


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Acyclovir Drug Manufacturers, Suppliers and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations and End-Use Industries

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Application
  • Hospital
  • Drug Store
By Form
  • Oral
  • Topical
  • Injection

By Distribution Channel
  • Hypermarkets/Supermarkets
  • Drugstores
  • Online Retails
  • Independent Retailers and Discounters

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Drug Stores in Emerging Countries
      • 3.2.2. Rising Number of Skin Infection Diseases Especially With Pregnant Women
      • 3.2.3. Growing Demand for Topical Dermatological Drugs
    • 3.3. Market Challenges
      • 3.3.1. Increasing Side Effects Such As Nausea, Vomiting, Diarrhoea, General Ill Feeling, Headache
    • 3.4. Market Trends
      • 3.4.1. Technology Advancement in Manufacturing Processes
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Acyclovir Drug, by Application, Form, Distribution Channel and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Acyclovir Drug (Value)
      • 5.2.1. Global Acyclovir Drug by: Application (Value)
        • 5.2.1.1. Hospital
        • 5.2.1.2. Drug Store
      • 5.2.2. Global Acyclovir Drug by: Form (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Topical
        • 5.2.2.3. Injection
      • 5.2.3. Global Acyclovir Drug by: Distribution Channel (Value)
        • 5.2.3.1. Hypermarkets/Supermarkets
        • 5.2.3.2. Drugstores
        • 5.2.3.3. Online Retails
        • 5.2.3.4. Independent Retailers and Discounters
      • 5.2.4. Global Acyclovir Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Acyclovir Drug (Volume)
      • 5.3.1. Global Acyclovir Drug by: Application (Volume)
        • 5.3.1.1. Hospital
        • 5.3.1.2. Drug Store
      • 5.3.2. Global Acyclovir Drug by: Form (Volume)
        • 5.3.2.1. Oral
        • 5.3.2.2. Topical
        • 5.3.2.3. Injection
      • 5.3.3. Global Acyclovir Drug by: Distribution Channel (Volume)
        • 5.3.3.1. Hypermarkets/Supermarkets
        • 5.3.3.2. Drugstores
        • 5.3.3.3. Online Retails
        • 5.3.3.4. Independent Retailers and Discounters
      • 5.3.4. Global Acyclovir Drug Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Acyclovir Drug (Price)
  • 6. Acyclovir Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GSK (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Zydus Pharmaceuticals (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mylan (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bausch Health (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Vectans Pharma (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Fresenius Kabi (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Aurobindo Pharma (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceutical Industries (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Heritage Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. APOTEX (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Acyclovir Drug Sale, by Application, Form, Distribution Channel and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Acyclovir Drug (Value)
      • 7.2.1. Global Acyclovir Drug by: Application (Value)
        • 7.2.1.1. Hospital
        • 7.2.1.2. Drug Store
      • 7.2.2. Global Acyclovir Drug by: Form (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Topical
        • 7.2.2.3. Injection
      • 7.2.3. Global Acyclovir Drug by: Distribution Channel (Value)
        • 7.2.3.1. Hypermarkets/Supermarkets
        • 7.2.3.2. Drugstores
        • 7.2.3.3. Online Retails
        • 7.2.3.4. Independent Retailers and Discounters
      • 7.2.4. Global Acyclovir Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Acyclovir Drug (Volume)
      • 7.3.1. Global Acyclovir Drug by: Application (Volume)
        • 7.3.1.1. Hospital
        • 7.3.1.2. Drug Store
      • 7.3.2. Global Acyclovir Drug by: Form (Volume)
        • 7.3.2.1. Oral
        • 7.3.2.2. Topical
        • 7.3.2.3. Injection
      • 7.3.3. Global Acyclovir Drug by: Distribution Channel (Volume)
        • 7.3.3.1. Hypermarkets/Supermarkets
        • 7.3.3.2. Drugstores
        • 7.3.3.3. Online Retails
        • 7.3.3.4. Independent Retailers and Discounters
      • 7.3.4. Global Acyclovir Drug Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Acyclovir Drug (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Acyclovir Drug: by Application(USD Million)
  • Table 2. Acyclovir Drug Hospital , by Region USD Million (2013-2018)
  • Table 3. Acyclovir Drug Drug Store , by Region USD Million (2013-2018)
  • Table 4. Acyclovir Drug: by Form(USD Million)
  • Table 5. Acyclovir Drug Oral , by Region USD Million (2013-2018)
  • Table 6. Acyclovir Drug Topical , by Region USD Million (2013-2018)
  • Table 7. Acyclovir Drug Injection , by Region USD Million (2013-2018)
  • Table 8. Acyclovir Drug: by Distribution Channel(USD Million)
  • Table 9. Acyclovir Drug Hypermarkets/Supermarkets , by Region USD Million (2013-2018)
  • Table 10. Acyclovir Drug Drugstores , by Region USD Million (2013-2018)
  • Table 11. Acyclovir Drug Online Retails , by Region USD Million (2013-2018)
  • Table 12. Acyclovir Drug Independent Retailers and Discounters , by Region USD Million (2013-2018)
  • Table 13. South America Acyclovir Drug, by Country USD Million (2013-2018)
  • Table 14. South America Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 15. South America Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 16. South America Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 17. Brazil Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 18. Brazil Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 19. Brazil Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 20. Argentina Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 21. Argentina Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 22. Argentina Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 23. Rest of South America Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 24. Rest of South America Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 25. Rest of South America Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 26. Asia Pacific Acyclovir Drug, by Country USD Million (2013-2018)
  • Table 27. Asia Pacific Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 28. Asia Pacific Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 29. Asia Pacific Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 30. China Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 31. China Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 32. China Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 33. Japan Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 34. Japan Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 35. Japan Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 36. India Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 37. India Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 38. India Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 39. South Korea Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 40. South Korea Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 41. South Korea Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 42. Taiwan Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 43. Taiwan Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 44. Taiwan Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 45. Australia Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 46. Australia Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 47. Australia Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 48. Rest of Asia-Pacific Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 49. Rest of Asia-Pacific Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 50. Rest of Asia-Pacific Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 51. Europe Acyclovir Drug, by Country USD Million (2013-2018)
  • Table 52. Europe Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 53. Europe Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 54. Europe Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 55. Germany Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 56. Germany Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 57. Germany Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 58. France Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 59. France Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 60. France Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 61. Italy Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 62. Italy Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 63. Italy Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 64. United Kingdom Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 65. United Kingdom Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 66. United Kingdom Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 67. Netherlands Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 68. Netherlands Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 69. Netherlands Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 70. Rest of Europe Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 71. Rest of Europe Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 72. Rest of Europe Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 73. MEA Acyclovir Drug, by Country USD Million (2013-2018)
  • Table 74. MEA Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 75. MEA Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 76. MEA Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 77. Middle East Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 78. Middle East Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 79. Middle East Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 80. Africa Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 81. Africa Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 82. Africa Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 83. North America Acyclovir Drug, by Country USD Million (2013-2018)
  • Table 84. North America Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 85. North America Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 86. North America Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 87. United States Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 88. United States Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 89. United States Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 90. Canada Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 91. Canada Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 92. Canada Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 93. Mexico Acyclovir Drug, by Application USD Million (2013-2018)
  • Table 94. Mexico Acyclovir Drug, by Form USD Million (2013-2018)
  • Table 95. Mexico Acyclovir Drug, by Distribution Channel USD Million (2013-2018)
  • Table 96. Acyclovir Drug Sales: by Application(K Units)
  • Table 97. Acyclovir Drug Sales Hospital , by Region K Units (2013-2018)
  • Table 98. Acyclovir Drug Sales Drug Store , by Region K Units (2013-2018)
  • Table 99. Acyclovir Drug Sales: by Form(K Units)
  • Table 100. Acyclovir Drug Sales Oral , by Region K Units (2013-2018)
  • Table 101. Acyclovir Drug Sales Topical , by Region K Units (2013-2018)
  • Table 102. Acyclovir Drug Sales Injection , by Region K Units (2013-2018)
  • Table 103. Acyclovir Drug Sales: by Distribution Channel(K Units)
  • Table 104. Acyclovir Drug Sales Hypermarkets/Supermarkets , by Region K Units (2013-2018)
  • Table 105. Acyclovir Drug Sales Drugstores , by Region K Units (2013-2018)
  • Table 106. Acyclovir Drug Sales Online Retails , by Region K Units (2013-2018)
  • Table 107. Acyclovir Drug Sales Independent Retailers and Discounters , by Region K Units (2013-2018)
  • Table 108. South America Acyclovir Drug Sales, by Country K Units (2013-2018)
  • Table 109. South America Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 110. South America Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 111. South America Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 112. Brazil Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 113. Brazil Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 114. Brazil Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 115. Argentina Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 116. Argentina Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 117. Argentina Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 118. Rest of South America Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 119. Rest of South America Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 120. Rest of South America Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 121. Asia Pacific Acyclovir Drug Sales, by Country K Units (2013-2018)
  • Table 122. Asia Pacific Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 123. Asia Pacific Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 124. Asia Pacific Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 125. China Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 126. China Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 127. China Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 128. Japan Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 129. Japan Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 130. Japan Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 131. India Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 132. India Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 133. India Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 134. South Korea Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 135. South Korea Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 136. South Korea Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 137. Taiwan Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 138. Taiwan Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 139. Taiwan Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 140. Australia Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 141. Australia Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 142. Australia Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 143. Rest of Asia-Pacific Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 144. Rest of Asia-Pacific Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 145. Rest of Asia-Pacific Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 146. Europe Acyclovir Drug Sales, by Country K Units (2013-2018)
  • Table 147. Europe Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 148. Europe Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 149. Europe Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 150. Germany Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 151. Germany Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 152. Germany Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 153. France Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 154. France Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 155. France Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 156. Italy Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 157. Italy Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 158. Italy Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 159. United Kingdom Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 160. United Kingdom Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 161. United Kingdom Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 162. Netherlands Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 163. Netherlands Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 164. Netherlands Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 165. Rest of Europe Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 166. Rest of Europe Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 167. Rest of Europe Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 168. MEA Acyclovir Drug Sales, by Country K Units (2013-2018)
  • Table 169. MEA Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 170. MEA Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 171. MEA Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 172. Middle East Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 173. Middle East Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 174. Middle East Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 175. Africa Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 176. Africa Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 177. Africa Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 178. North America Acyclovir Drug Sales, by Country K Units (2013-2018)
  • Table 179. North America Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 180. North America Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 181. North America Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 182. United States Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 183. United States Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 184. United States Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 185. Canada Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 186. Canada Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 187. Canada Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 188. Mexico Acyclovir Drug Sales, by Application K Units (2013-2018)
  • Table 189. Mexico Acyclovir Drug Sales, by Form K Units (2013-2018)
  • Table 190. Mexico Acyclovir Drug Sales, by Distribution Channel K Units (2013-2018)
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Acyclovir Drug: by Application(USD Million)
  • Table 202. Acyclovir Drug Hospital , by Region USD Million (2019-2024)
  • Table 203. Acyclovir Drug Drug Store , by Region USD Million (2019-2024)
  • Table 204. Acyclovir Drug: by Form(USD Million)
  • Table 205. Acyclovir Drug Oral , by Region USD Million (2019-2024)
  • Table 206. Acyclovir Drug Topical , by Region USD Million (2019-2024)
  • Table 207. Acyclovir Drug Injection , by Region USD Million (2019-2024)
  • Table 208. Acyclovir Drug: by Distribution Channel(USD Million)
  • Table 209. Acyclovir Drug Hypermarkets/Supermarkets , by Region USD Million (2019-2024)
  • Table 210. Acyclovir Drug Drugstores , by Region USD Million (2019-2024)
  • Table 211. Acyclovir Drug Online Retails , by Region USD Million (2019-2024)
  • Table 212. Acyclovir Drug Independent Retailers and Discounters , by Region USD Million (2019-2024)
  • Table 213. South America Acyclovir Drug, by Country USD Million (2019-2024)
  • Table 214. South America Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 215. South America Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 216. South America Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 217. Brazil Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 218. Brazil Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 219. Brazil Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 220. Argentina Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 221. Argentina Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 222. Argentina Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 223. Rest of South America Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 224. Rest of South America Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 225. Rest of South America Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 226. Asia Pacific Acyclovir Drug, by Country USD Million (2019-2024)
  • Table 227. Asia Pacific Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 228. Asia Pacific Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 229. Asia Pacific Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 230. China Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 231. China Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 232. China Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 233. Japan Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 234. Japan Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 235. Japan Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 236. India Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 237. India Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 238. India Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 239. South Korea Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 240. South Korea Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 241. South Korea Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 242. Taiwan Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 243. Taiwan Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 244. Taiwan Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 245. Australia Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 246. Australia Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 247. Australia Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 248. Rest of Asia-Pacific Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 249. Rest of Asia-Pacific Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 250. Rest of Asia-Pacific Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 251. Europe Acyclovir Drug, by Country USD Million (2019-2024)
  • Table 252. Europe Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 253. Europe Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 254. Europe Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 255. Germany Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 256. Germany Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 257. Germany Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 258. France Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 259. France Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 260. France Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 261. Italy Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 262. Italy Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 263. Italy Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 264. United Kingdom Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 265. United Kingdom Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 266. United Kingdom Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 267. Netherlands Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 268. Netherlands Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 269. Netherlands Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 270. Rest of Europe Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 271. Rest of Europe Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 272. Rest of Europe Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 273. MEA Acyclovir Drug, by Country USD Million (2019-2024)
  • Table 274. MEA Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 275. MEA Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 276. MEA Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 277. Middle East Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 278. Middle East Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 279. Middle East Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 280. Africa Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 281. Africa Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 282. Africa Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 283. North America Acyclovir Drug, by Country USD Million (2019-2024)
  • Table 284. North America Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 285. North America Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 286. North America Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 287. United States Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 288. United States Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 289. United States Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 290. Canada Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 291. Canada Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 292. Canada Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 293. Mexico Acyclovir Drug, by Application USD Million (2019-2024)
  • Table 294. Mexico Acyclovir Drug, by Form USD Million (2019-2024)
  • Table 295. Mexico Acyclovir Drug, by Distribution Channel USD Million (2019-2024)
  • Table 296. Acyclovir Drug Sales: by Application(K Units)
  • Table 297. Acyclovir Drug Sales Hospital , by Region K Units (2019-2024)
  • Table 298. Acyclovir Drug Sales Drug Store , by Region K Units (2019-2024)
  • Table 299. Acyclovir Drug Sales: by Form(K Units)
  • Table 300. Acyclovir Drug Sales Oral , by Region K Units (2019-2024)
  • Table 301. Acyclovir Drug Sales Topical , by Region K Units (2019-2024)
  • Table 302. Acyclovir Drug Sales Injection , by Region K Units (2019-2024)
  • Table 303. Acyclovir Drug Sales: by Distribution Channel(K Units)
  • Table 304. Acyclovir Drug Sales Hypermarkets/Supermarkets , by Region K Units (2019-2024)
  • Table 305. Acyclovir Drug Sales Drugstores , by Region K Units (2019-2024)
  • Table 306. Acyclovir Drug Sales Online Retails , by Region K Units (2019-2024)
  • Table 307. Acyclovir Drug Sales Independent Retailers and Discounters , by Region K Units (2019-2024)
  • Table 308. South America Acyclovir Drug Sales, by Country K Units (2019-2024)
  • Table 309. South America Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 310. South America Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 311. South America Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 312. Brazil Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 313. Brazil Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 314. Brazil Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 315. Argentina Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 316. Argentina Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 317. Argentina Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 318. Rest of South America Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 319. Rest of South America Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 320. Rest of South America Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 321. Asia Pacific Acyclovir Drug Sales, by Country K Units (2019-2024)
  • Table 322. Asia Pacific Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 323. Asia Pacific Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 324. Asia Pacific Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 325. China Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 326. China Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 327. China Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 328. Japan Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 329. Japan Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 330. Japan Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 331. India Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 332. India Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 333. India Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 334. South Korea Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 335. South Korea Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 336. South Korea Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 337. Taiwan Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 338. Taiwan Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 339. Taiwan Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 340. Australia Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 341. Australia Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 342. Australia Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 343. Rest of Asia-Pacific Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 344. Rest of Asia-Pacific Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 345. Rest of Asia-Pacific Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 346. Europe Acyclovir Drug Sales, by Country K Units (2019-2024)
  • Table 347. Europe Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 348. Europe Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 349. Europe Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 350. Germany Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 351. Germany Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 352. Germany Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 353. France Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 354. France Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 355. France Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 356. Italy Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 357. Italy Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 358. Italy Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 359. United Kingdom Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 360. United Kingdom Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 361. United Kingdom Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 362. Netherlands Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 363. Netherlands Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 364. Netherlands Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 365. Rest of Europe Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 366. Rest of Europe Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 367. Rest of Europe Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 368. MEA Acyclovir Drug Sales, by Country K Units (2019-2024)
  • Table 369. MEA Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 370. MEA Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 371. MEA Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 372. Middle East Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 373. Middle East Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 374. Middle East Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 375. Africa Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 376. Africa Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 377. Africa Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 378. North America Acyclovir Drug Sales, by Country K Units (2019-2024)
  • Table 379. North America Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 380. North America Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 381. North America Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 382. United States Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 383. United States Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 384. United States Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 385. Canada Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 386. Canada Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 387. Canada Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 388. Mexico Acyclovir Drug Sales, by Application K Units (2019-2024)
  • Table 389. Mexico Acyclovir Drug Sales, by Form K Units (2019-2024)
  • Table 390. Mexico Acyclovir Drug Sales, by Distribution Channel K Units (2019-2024)
  • Table 391. Research Programs/Design for This Report
  • Table 392. Key Data Information from Secondary Sources
  • Table 393. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Acyclovir Drug: by Application USD Million (2013-2018)
  • Figure 5. Global Acyclovir Drug: by Form USD Million (2013-2018)
  • Figure 6. Global Acyclovir Drug: by Distribution Channel USD Million (2013-2018)
  • Figure 7. South America Acyclovir Drug Share (%), by Country
  • Figure 8. Asia Pacific Acyclovir Drug Share (%), by Country
  • Figure 9. Europe Acyclovir Drug Share (%), by Country
  • Figure 10. MEA Acyclovir Drug Share (%), by Country
  • Figure 11. North America Acyclovir Drug Share (%), by Country
  • Figure 12. Global Acyclovir Drug: by Application K Units (2013-2018)
  • Figure 13. Global Acyclovir Drug: by Form K Units (2013-2018)
  • Figure 14. Global Acyclovir Drug: by Distribution Channel K Units (2013-2018)
  • Figure 15. South America Acyclovir Drug Share (%), by Country
  • Figure 16. Asia Pacific Acyclovir Drug Share (%), by Country
  • Figure 17. Europe Acyclovir Drug Share (%), by Country
  • Figure 18. MEA Acyclovir Drug Share (%), by Country
  • Figure 19. North America Acyclovir Drug Share (%), by Country
  • Figure 20. Global Acyclovir Drug share by Players 2018 (%)
  • Figure 21. Global Acyclovir Drug share by Players (Top 3) 2018(%)
  • Figure 22. Global Acyclovir Drug share by Players (Top 5) 2018(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. GSK (United Kingdom) Revenue: by Geography 2018
  • Figure 26. Zydus Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 27. Zydus Pharmaceuticals (United States) Revenue: by Geography 2018
  • Figure 28. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 29. Mylan (United States) Revenue: by Geography 2018
  • Figure 30. Bausch Health (Canada) Revenue, Net Income and Gross profit
  • Figure 31. Bausch Health (Canada) Revenue: by Geography 2018
  • Figure 32. Vectans Pharma (France) Revenue, Net Income and Gross profit
  • Figure 33. Vectans Pharma (France) Revenue: by Geography 2018
  • Figure 34. Fresenius Kabi (Germany) Revenue, Net Income and Gross profit
  • Figure 35. Fresenius Kabi (Germany) Revenue: by Geography 2018
  • Figure 36. Aurobindo Pharma (India) Revenue, Net Income and Gross profit
  • Figure 37. Aurobindo Pharma (India) Revenue: by Geography 2018
  • Figure 38. Teva Pharmaceutical Industries (Israel) Revenue, Net Income and Gross profit
  • Figure 39. Teva Pharmaceutical Industries (Israel) Revenue: by Geography 2018
  • Figure 40. Heritage Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 41. Heritage Pharmaceuticals (United States) Revenue: by Geography 2018
  • Figure 42. APOTEX (Canada) Revenue, Net Income and Gross profit
  • Figure 43. APOTEX (Canada) Revenue: by Geography 2018
  • Figure 44. Global Acyclovir Drug: by Application USD Million (2019-2024)
  • Figure 45. Global Acyclovir Drug: by Form USD Million (2019-2024)
  • Figure 46. Global Acyclovir Drug: by Distribution Channel USD Million (2019-2024)
  • Figure 47. South America Acyclovir Drug Share (%), by Country
  • Figure 48. Asia Pacific Acyclovir Drug Share (%), by Country
  • Figure 49. Europe Acyclovir Drug Share (%), by Country
  • Figure 50. MEA Acyclovir Drug Share (%), by Country
  • Figure 51. North America Acyclovir Drug Share (%), by Country
  • Figure 52. Global Acyclovir Drug: by Application K Units (2019-2024)
  • Figure 53. Global Acyclovir Drug: by Form K Units (2019-2024)
  • Figure 54. Global Acyclovir Drug: by Distribution Channel K Units (2019-2024)
  • Figure 55. South America Acyclovir Drug Share (%), by Country
  • Figure 56. Asia Pacific Acyclovir Drug Share (%), by Country
  • Figure 57. Europe Acyclovir Drug Share (%), by Country
  • Figure 58. MEA Acyclovir Drug Share (%), by Country
  • Figure 59. North America Acyclovir Drug Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • GSK (United Kingdom)
  • Zydus Pharmaceuticals (United States)
  • Mylan (United States)
  • Bausch Health (Canada)
  • Vectans Pharma (France)
  • Fresenius Kabi (Germany)
  • Aurobindo Pharma (India)
  • Teva Pharmaceutical Industries (Israel)
  • Heritage Pharmaceuticals (United States)
  • APOTEX (Canada)
Additional players considered in the study are as follows:
Cadila Pharmaceuticals (India) , Amneal Pharmaceuticals (United States) , Taro Pharmaceutical (United States) , Glenmark (India) , G&W Laboratories (United States) , Yiling Pharmaceutical Ltd. (China) , Alembic Pharmaceuticals (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation